Savola JM - Search Results

1

Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.

Sallinen J, Höglund I, Engström M, Lehtimäki J, Virtanen R, Sirviö J, Wurster S, Savola JM, Haapalinna A. Sallinen J, et al. Among authors: savola jm. Br J Pharmacol. 2007 Feb;150(4):391-402. doi: 10.1038/sj.bjp.0707005. Epub 2007 Jan 15. Br J Pharmacol. 2007. PMID: 17220913 Free PMC article.

2

Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine.

Savola JM, Virtanen R. Savola JM, et al. Eur J Pharmacol. 1991 Mar 26;195(2):193-9. doi: 10.1016/0014-2999(91)90535-x. Eur J Pharmacol. 1991. PMID: 1678707

3

Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist.

Virtanen R, Savola JM, Saano V, Nyman L. Virtanen R, et al. Among authors: savola jm. Eur J Pharmacol. 1988 May 20;150(1-2):9-14. doi: 10.1016/0014-2999(88)90744-3. Eur J Pharmacol. 1988. PMID: 2900154

4

Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine.

Haapalinna A, Viitamaa T, MacDonald E, Savola JM, Tuomisto L, Virtanen R, Heinonen E. Haapalinna A, et al. Among authors: savola jm. Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):570-82. doi: 10.1007/pl00005092. Naunyn Schmiedebergs Arch Pharmacol. 1997. PMID: 9402036

5

Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole.

Virtanen R, Savola JM, Saano V. Virtanen R, et al. Among authors: savola jm. Arch Int Pharmacodyn Ther. 1989 Jan-Feb;297:190-204. Arch Int Pharmacodyn Ther. 1989. PMID: 2567152

6

Anti-obesity effect of MPV-1743 A III, a novel imidazoline derivative, in genetic obesity.

Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R. Savontaus E, et al. Among authors: savola jm. Eur J Pharmacol. 1997 Jun 11;328(2-3):207-15. doi: 10.1016/s0014-2999(97)83047-6. Eur J Pharmacol. 1997. PMID: 9218703

7

Protean agonism at alpha2A-adrenoceptors.

Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R, Savola JM, Cockcroft V, Akerman KE. Jansson CC, et al. Among authors: savola jm. Mol Pharmacol. 1998 May;53(5):963-8. Mol Pharmacol. 1998. PMID: 9584224

8

Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner.

Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M. Jansson CC, et al. Among authors: savola jm. Eur J Pharmacol. 1999 Jun 11;374(1):137-46. doi: 10.1016/s0014-2999(99)00306-4. Eur J Pharmacol. 1999. PMID: 10422650

9

Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine.

Nyrönen T, Pihlavisto M, Peltonen JM, Hoffrén AM, Varis M, Salminen T, Wurster S, Marjamäki A, Kanerva L, Katainen E, Laaksonen L, Savola JM, Scheinin M, Johnson MS. Nyrönen T, et al. Among authors: savola jm. Mol Pharmacol. 2001 May;59(5):1343-54. doi: 10.1124/mol.59.5.1343. Mol Pharmacol. 2001. PMID: 11306720

10

Identification and characterization of the imidazoline I2b-binding sites in the hamster brown adipose tissue as a study model for imidazoline receptors.

Römer L, Wurster S, Savola JM, Raasmaja A. Römer L, et al. Among authors: savola jm. Arch Physiol Biochem. 2003 Apr;111(2):159-66. doi: 10.1076/apab.111.2.159.14006. Arch Physiol Biochem. 2003. PMID: 12919003

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page